A5100359374- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Click Chemistry and Applications
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Fungal Plant Pathogen Control
- Neutropenia and Cancer Infections
- Mesenchymal stem cell research
- Polyomavirus and related diseases
- Histone Deacetylase Inhibitors Research
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Fibroblast Growth Factor Research
- Epigenetics and DNA Methylation
- Retinoids in leukemia and cellular processes
- Neuroendocrine Tumor Research Advances
- Kruppel-like factors research
Eulji University
2021-2025
Uijeongbu St. Mary's Hospital
2006-2025
Institute of Hematology & Blood Diseases Hospital
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
Jena University Hospital
2024
Charité - Universitätsmedizin Berlin
2024
California Institute of Technology
2019-2024
Eulji General Hospital
2022-2024
Cancer Research Institute
2024
Korea Disease Control and Prevention Agency
2023
Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety nilotinib, as compared with imatinib, in patients newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) phase.In this phase 3, randomized, open-label, multicenter study, we assigned 846 chronic-phase CML 1:1:1 ratio receive nilotinib (at dose either 300 mg or 400 twice daily) imatinib once daily). The primary end point was rate major molecular...
Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated in vitro. Phase II studies have demonstrated efficacy and safety with dasatinib 70 mg twice daily chronic-phase (CP) chronic myelogenous leukemia (CML) after treatment failure. In phase I, responses occurred once-daily administration despite only intermittent inhibition. Once-daily resulted less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, dose-...
Insulin resistance plays a primary role in the development of type 2 diabetes and may be related to alterations fat metabolism. Recent studies have suggested that local accumulation metabolites inside skeletal muscle activate serine kinase cascade involving protein C–θ (PKC-θ), leading defects insulin signaling glucose transport muscle. To test this hypothesis, we examined whether mice with inactivation PKC-θ are protected from fat-induced Skeletal hepatic action as assessed during...
Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib newly diagnosed, chronic-phase chronic myeloid leukemia (CML).A total of 502 patients were randomly assigned 1:1 to 500 mg per day or 400 day.The complete cytogenetic response (CCyR) rate at 12 months was not different for (70%; 95% CI, 64% 76%) versus (68%; 62% 74%; two-sided P = .601); therefore, the study did...
Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed the efficacy safety of bosutinib versus imatinib first-line treatment chronic-phase CML. Methods In this ongoing, multinational, phase III study, 536 patients newly diagnosed CML were randomly assigned 1:1 receive 400 mg once daily (n = 268) or 268). Per protocol, was in who typical...
Imatinib slows development of chronic myeloid leukemia (CML). However, available information on morbidity and mortality is largely based sponsored trials, whereas independent long-term field studies are lacking. Consecutive CML patients who started imatinib treatment before 2005 were in complete cytogenetic remission (CCyR) after 2 years (±3 months) eligible for enrollment the multicenter Long-Term (Side) Effects (ILTE) study. Incidence first serious nonserious adverse events loss CCyR...
Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking into inactive conformation through mechanism distinct from those for all other ABL kinase inhibitors. targets both native and mutated BCR-ABL1, including gatekeeper T315I mutant. The safety antileukemic activity asciminib in patients with Philadelphia chromosome-positive leukemia are unknown.
Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in phase (CP; CML-CP) and accelerated (AP; CML-AP) who are resistant to or intolerant prior imatinib therapy. In this subanalysis II study nilotinib imatinib-resistant imatinib-intolerant CML-CP, occurrence impact baseline newly detectable BCR-ABL mutations were assessed.Baseline mutation data assessed 281 (88%) 321 CML-CP registration trial.Among patients,...
Purpose To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 in patients newly diagnosed chronic myeloid leukemia phase. Patients Methods A total 476 were randomly assigned 2:1 to (n = 319) or 157) daily. The primary end point was major molecular response (MMR) rate at 12 months. Results At months, differences MMR complete cytogenetic (CCyR) rates not statistically significant (MMR, 46% v 40%; P .2035; CCyR, 70% 66%; .3470)....
Abstract In the ENESTnd study, with ≥10 years follow-up in patients newly diagnosed chronic myeloid leukemia (CML) phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death, increased eligibility for treatment-free remission (TFR). Cumulative 10-year MMR MR 4.5 were (300 mg twice daily [BID], 77.7% 61.0%, respectively; 400 BID, 79.7% 61.2%, respectively) than imatinib (400 once [QD], 62.5% 39.2%, respectively). TFR at...
Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication disease. Digital‐PCR (dPCR), able detect 1 positive cell out 10 7 , has been recently developed. The ISAV study a multicentre trial aimed at validating dPCR predict relapses after imatinib discontinuation in CML patients with Q‐RT‐PCR. under therapy since more than 2 years and PCR least 18 months were eligible. Patients monitored standard 36...